Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.
IPO Year:
Exchange: NASDAQ
Website: viatris.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/19/2024 | $15.00 | Buy | Jefferies |
10/23/2023 | $13.00 → $9.00 | Neutral → Underperform | BofA Securities |
6/23/2023 | $11.00 | Equal Weight → Underweight | Barclays |
4/24/2023 | $11.00 | Overweight → Equal Weight | Barclays |
2/17/2023 | $16.00 → $14.00 | Outperform → Market Perform | BMO Capital Markets |
1/27/2023 | $13.00 → $15.00 | Hold → Buy | Jefferies |
11/10/2022 | $9.00 → $12.00 | Sell → Neutral | UBS |
11/8/2022 | $10.00 | Underweight → Neutral | Piper Sandler |
10/21/2022 | $11.00 | Hold | Jefferies |
6/14/2022 | $9.00 | Sell | UBS |
Jefferies resumed coverage of Viatris with a rating of Buy and set a new price target of $15.00
BofA Securities downgraded Viatris from Neutral to Underperform and set a new price target of $9.00 from $13.00 previously
Barclays downgraded Viatris from Equal Weight to Underweight and set a new price target of $11.00
Barclays downgraded Viatris from Overweight to Equal Weight and set a new price target of $11.00
BMO Capital Markets downgraded Viatris from Outperform to Market Perform and set a new price target of $14.00 from $16.00 previously
Jefferies upgraded Viatris from Hold to Buy and set a new price target of $15.00 from $13.00 previously
UBS upgraded Viatris from Sell to Neutral and set a new price target of $12.00 from $9.00 previously
Piper Sandler upgraded Viatris from Underweight to Neutral and set a new price target of $10.00
Jefferies resumed coverage of Viatris with a rating of Hold and set a new price target of $11.00
UBS initiated coverage of Viatris with a rating of Sell and set a new price target of $9.00
PITTSBURGH, Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS, ", Viatris", or the ", Company", ))) announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acquisition" and, together with Viatris and Mylan, the "Offerors" and each, an "Offeror"), have commenced tender offers (each individually, with respect to a series of notes, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for cash (1) any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes"), (2) any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan (the "Mylan Notes" and, together with the Viatris No
Late-Breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients can be considered safe and well-tolerated Data shows a clinically meaningful improvement in disease activity consistent with results from other global Phase 2 studies of cenerimod PITTSBURGH, Aug. 23, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, presented today the results of one of its Phase 2 studies* of cenerimod (ACT-333441). The ACT-333441 study was accepted as a late-breaking abstract and was presented during an oral presentation at the 26th Asia-Pacific League of Associations for Rheumatology (APLAR) Annua
PITTSBURGH, Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1]Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across SegmentsU.S. GAAP Net Loss was $326 Million; Adjusted EBITDA Grew ~2% to $1.2 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was a Loss of $0.27 per Share; Adjusted EPS Grew ~3% to $0.69 per Share on a Divestiture-Adjusted Basis[2]Completion of Divestitures Marks Inflection Point in Company's Move Towards Accelerated Growth and Shareholder ReturnRaises 2024 F
PITTSBURGH, Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024, to shareholders of record as of the close of business on August 23, 2024. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provi
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth PITTSBURGH, July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures. In October, the Company announced it had entered into agreements to divest substantially all of its OTC business, as well as its Women's Healthcare business, its Active Pharmac
PITTSBURGH, July 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ("DOJ") has advised that it no longer considers Mylan, and its former President, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry. The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products. This outcome affirms the Company's longstanding position, which it has consistently maintained and asserted, for many years, that Mylan investigated these allegations t
PITTSBURGH, June 7, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditiona
PITTSBURGH, June 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, June 11, 2024. Chief Executive Officer Scott A Smith and Company executives will represent the company in a fireside chat scheduled at 9:20 a.m. ET. Interested parties can access a live webcast of the event at investor.viatris.com. An archived version also will be available following the live event and can be accessed at the same location for a limited time. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare com
PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit
PITTSBURGH, May 31, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the company will participate in the Jeffries Global Healthcare Conference at the Marriott Marquis Hotel in New York, NY on Thursday, June 6, 2024. Chief Executive Officer Scott A. Smith and Company executives will represent the company in a fireside chat scheduled at 8 a.m. ET. Interested parties can access a live webcast of the event at investor.viatris.com. An archived version also will be available following the live event and can be accessed at the same location for a limited time. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to
PITTSBURGH, Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1]Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across SegmentsU.S. GAAP Net Loss was $326 Million; Adjusted EBITDA Grew ~2% to $1.2 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was a Loss of $0.27 per Share; Adjusted EPS Grew ~3% to $0.69 per Share on a Divestiture-Adjusted Basis[2]Completion of Divestitures Marks Inflection Point in Company's Move Towards Accelerated Growth and Shareholder ReturnRaises 2024 F
PITTSBURGH, Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024, to shareholders of record as of the close of business on August 23, 2024. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provi
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth PITTSBURGH, July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures. In October, the Company announced it had entered into agreements to divest substantially all of its OTC business, as well as its Women's Healthcare business, its Active Pharmac
PITTSBURGH, June 7, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditiona
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. "Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™," said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire. "We have been engaged in productive dialogue with the U.S. Food and Drug Administration (FDA) with respect to our submitted Special Protocol Assessmen
PITTSBURGH, May 9, 2024 /PRNewswire/ -- Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Operating Activities of $615 Million; and Free Cash Flow of $565 Million for the First Quarter Reports Fourth Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis[1] Reaffirms 2024 New Product Revenue Range of $450 Million to $550 Million Closes Idorsia Transaction, Expanding Portfolio of Innovative Assets Closes Women's Healthcare Business Divestiture Reaffirms 2024 Financial Guidance After Adjusting the Ranges Solely to Reflect t
PITTSBURGH, April 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional
PITTSBURGH, Feb. 28, 2024 /PRNewswire/ -- Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1] Reports 2023 Total Revenues of $15.4 Billion, U.S. GAAP Net Earnings of $54.7 Million, Adjusted EBITDA of $5.1 Billion, U.S. GAAP Net Cash Provided by Operating Activities of $2.8 Billion and Free Cash Flow of $2.4 Billion Reports Third Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis in 2023 and Expects to see Continued Growth in 2024[2] Immediately Adds Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential, Through Global Research and Development Collaboration With Idorsia; Announces R&D Event to be Held
PITTSBURGH, Oct. 10, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) plans to release its third quarter 2023 financial results on Tuesday, November 7 after the close of the U.S. financial markets. Chief Executive Officer Scott A. Smith, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 5:00 p.m. ET on November 7 to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800.274.8461 or 203.518.9783 for international callers (Conference ID: VTRSQ323). A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ: VTRS) is a glo
Total Gross Proceeds From All Divestitures, Including the 2022 Divestiture of the Company's Biosimilars Business, and the Estimated Retained Value are in Line with the Company's Previously Communicated RangeStrategic Decision Made to Retain Rights and Opportunities for Viagra®, Dymista® and Select Over-the-Counter (OTC) Products in Certain Markets Representing Approximately $1.6B in Estimated Retained ValueTotal Transactions Value Represents up to $6.94B of Total Gross Proceeds Which Represents an Accretive Multiple of 12.4x [1]Offer for Substantially All of OTC Business Reflects Gross Consideration of up to Approximately $2.17B, Representing an Estimated Accretive Multiple of 12.8x; Definit
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
3 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
3 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Warner Bros. Discovery, Inc. (NASDAQ:WBD) stock escalated 18.28% after a report that the company had discussed plans to split its digital streaming and studio businesses from its legacy television networks. MicroStrategy Inc.’s (NASDAQ:MSTR) stock gained 16.74% last week amid a rise in Bitcoin’s price. D.R. Horton, Inc. (NYSE:DHI) shares surged 12.91% after the company reported better-than-expected Q3 financial results and revised FY24 guidance. The company also authorized a new $4 billion share repurchase. Few analysts raised the price forecasts on the stock. Coinbase Global Inc.’s
Jefferies analyst Glen Santangelo reinstates Viatris (NASDAQ:VTRS) with a Buy and announces $15 price target.
The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in Japan, with an estimated 33,000 patients in Japan* assumed to be suffering from this disease and with limited treatment options for IgAN patients in this country.
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future GrowthPITTSBURGH, July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures.
The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.
Viatris's (NYSE:VTRS) short percent of float has risen 9.41% since its last report. The company recently reported that it has 44.95 million shares sold short, which is 4.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.56 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is imp
Thursday, Viatris Inc (NASDAQ:VTRS) reported first-quarter EPS of $0.67, which is in line with the consensus. The company reported sales of $3.66 billion, missing the consensus of $3.69 billion. Total net sales declined 2% on a reported basis and increased 2% on a divestiture-adjusted operational basis. Brand sales fell 5% to $2.31 billion. The company says the performance reflects strong growth in Emerging Markets and Europe and expansion of business activities in JANZ, offset by unfavorable channel dynamics in North America and expected base business erosion resulting from government price regulations in Japan and Australia. Generic sales reached 1.34 billion, up 4%. Viatris says
Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising uptick in unemployment claims prompting speculation over Federal Reserve interest rate cuts. Jobless benefits rose from 209,000 to 231,000 in the week ending May 4, surpassing market expectations of 210,000 and reaching the highest level in eight months. Consequently, the U.S. dollar Index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:UUP), declined by 0.2% in reaction to the data, as market participants slightly increased bets on a September Fed cut. The S&P 500 index inched up by 0.1%, following Wednesday’s flat close, while blue chips
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)
PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit
PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas. Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology
Company thanks Sanjeev Narula for his role in the successful execution of Viatris' Phase 1 strategy; Narula will support a smooth CFO transition prior to his departure on March 1, 2024 PITTSBURGH, Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that, as it prepares to enter Phase 2 of its strategic plan, Theodora "Doretta" Mistras has been appointed Chief Financial Officer (CFO) effective March 1, 2024, and Philippe Martin has been appointed Chief R&D Officer with immediate effect. Current Viatris CFO Sanjeev Narula, who h
PITTSBURGH, May 22, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing board refreshment efforts, Leo Groothuis has been appointed as Viatris' newest member of its board of directors. Groothuis fills the vacancy created by the previous departure of Michael Goettler in April of this year. Groothuis has significant international experience and serves as General Counsel of HAL Investments, the Dutch investment subsidiary of HAL Holding N.V., an international investment company listed on the Amsterdam stock exchange, which is focused on increasing shareholder value. In addition to his strategic, financial and governance focus
8-K - Viatris Inc (0001792044) (Filer)
144 - Viatris Inc (0001792044) (Subject)
10-Q - Viatris Inc (0001792044) (Filer)
8-K - Viatris Inc (0001792044) (Filer)
8-K - Viatris Inc (0001792044) (Filer)
144 - Viatris Inc (0001792044) (Subject)
8-K - Viatris Inc (0001792044) (Filer)
10-Q - Viatris Inc (0001792044) (Filer)
8-K - Viatris Inc (0001792044) (Filer)
10-K/A - Viatris Inc (0001792044) (Filer)